1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

NAPRA Drug Scheduling Framework & National Model Standards of Practice

While federal statutes establish whether a substance is a prescription pharmaceutical (under Health Canada's Prescription Drug List) or a controlled substance (under the CDSA), the conditions under which non-prescription medications are distributed and accessed by the public are governed primarily at the provincial and territorial level. To establish regulatory uniformity across the country, provincial pharmacy regulatory authorities collaborate through the National Association of Pharmacy Regulatory Authorities (NAPRA).

---

Constitutional Division of Powers: Federal vs. Provincial Authority

A thorough grasp of Canadian pharmacy jurisprudence requires an understanding of how the Constitution Act, 1867 divides legislative authority between the federal Parliament and provincial legislatures:

1. Federal Authority (Section 91)

• Constitutional Basis: Criminal Law power [s. 91(27)], Trade and Commerce [s. 91(2)], and the general Peace, Order, and Good Government (POGG) clause.
• Regulatory Scope: Health Canada oversees drug safety, efficacy, and manufacturing quality; reviews pre-market New Drug Submissions (NDS); assigns DINs, NPNs, and NOCs; establishes the federal Prescription Drug List (PDL); and enforces prohibitions under the Food and Drugs Act and the Controlled Drugs and Substances Act.
• Key Limit: Federal law governs the product itself and its commercial importation, interprovincial transport, and baseline scheduling.

2. Provincial & Territorial Authority (Section 92)

• Constitutional Basis: Property and Civil Rights [s. 92(13)] and Matters of a Local or Private Nature [s. 92(16)].
• Regulatory Scope: Provincial and territorial Pharmacy Regulatory Authorities (PRAs, also known as provincial Colleges of Pharmacy) govern the practice of pharmacy and healthcare professionals. This includes:
  • Licensing and disciplining individual pharmacists, pharmacy technicians, and interns;
  • Licensing, inspecting, and establishing physical design standards for pharmacy premises;
  • Determining the professional scope of practice (e.g., prescribing for minor ailments, administering injections, adapting prescriptions, ordering laboratory tests);
  • Establishing provincial drug benefit formularies (e.g., Ontario Drug Benefit, RAMQ, BC PharmaCare);
  • Enacting provincial drug scheduling legislation that governs where and how non-prescription drugs are sold.

The "Stricter Standard" Rule and Federal Paramountcy

Under the constitutional Doctrine of Federal Paramountcy, if an irreconcilable operational conflict arises between valid federal and provincial legislation (such that obeying one requires disobeying the other), federal law prevails. In pharmacy practice, however, federal and provincial laws typically operate concurrently. The universal professional and legal rule is that the pharmacist must comply with whichever standard is more strict:

Example: The federal Controlled Substances Regulations require a pharmacy to retain controlled-substance prescription records for a minimum of 2 years. If the provincial College of Pharmacy mandates a minimum retention period of 10 years (or until 2 years past the age of majority for pediatrics), the pharmacist must retain the records for 10 years. Complying with the stricter provincial standard satisfies both provincial and federal law simultaneously.

---

The NAPRA National Drug Scheduling System

Established in 1995, the NAPRA National Drug Scheduling System provides a scientifically grounded, tiered framework that harmonizes conditions of drug sale across Canadian jurisdictions. Most provinces adopt NAPRA schedules directly by legislative reference (though Quebec operates an independent provincial scheduling system under its Loi sur la pharmacie).

The National Drug Scheduling Advisory Committee (NDSAC) evaluates drugs based on an objective cascading principle. The committee assesses active ingredients against established risk factors:

1. Is the drug used for an ailment that requires medical diagnosis and supervision?
2. Does the drug have a narrow margin of safety, severe toxicity, or serious drug interactions?
3. Does the drug present significant potential for misuse, abuse, habituation, or diversion?
4. Can the consumer safely self-diagnose the condition and monitor the response?
5. Is direct pharmacist intervention, patient assessment, or counseling necessary to ensure safe use?

                    [ Drug Evaluation by NDSAC ]
                                 │
                 Requires medical diagnosis/Rx?
                     ├─── YES ───> SCHEDULE I (Prescription)
                     │
                     └─── NO  ───> Requires direct pharmacist intervention?
                                       ├─── YES ───> SCHEDULE II (Behind-the-Counter)
                                       │
                                       └─── NO  ───> Requires pharmacy-only professional supervision?
                                                         ├─── YES ───> SCHEDULE III (Pharmacy Self-Selection)
                                                         │
                                                         └─── NO  ───> UNSCHEDULED (Any Retail Outlet)

---

Detailed Analysis of the Four NAPRA Schedules

Schedule I: Prescription Drugs

• Dispensing Requirement: Sold only pursuant to a valid prescription from an authorized practitioner (physician, dentist, nurse practitioner, veterinarian, or pharmacist where authorized by provincial scope).
• Regulatory Scope: Includes all chemical entities listed on Health Canada's Prescription Drug List (PDL), as well as narcotics, controlled drugs, and targeted substances governed by the CDSA and the Controlled Substances Regulations (low-dose codeine products sold under CSR s. 98(2) are the exception: they are Schedule II).
• Storage and Access: Must be retained within the secured dispensary area where the public has zero direct physical access.

Schedule II: "Behind-the-Counter" / Professional Intervention Required

• Dispensing Requirement: Available without a prescription, but strictly requires direct, personal intervention and professional assessment by a licensed pharmacist before release.
• Storage and Access: Must be stored in an area of the pharmacy with zero public access (behind the dispensary counter, inside a secure dispensary barrier, or in a locked cabinet).
• Pharmacist Obligations:
  • Conduct an individualized patient assessment (evaluate indication, contraindications, concurrent drug therapy, pregnancy/lactation status);
  • Confirm that the patient understands proper dosage, administration, expected outcomes, and red-flag symptoms requiring emergency medical evaluation;
  • Document the clinical encounter and transaction in the pharmacy management system (PMS) to maintain a complete patient medication profile;
  • Refuse sale if the product is clinically inappropriate or if drug misuse/dependency is suspected.
• Key Clinical Examples:
  • Low-dose codeine combination products sold without a prescription under CSR s. 98(2) (not more than 8 mg codeine phosphate per solid unit);
  • Sublingual immediate-release nitroglycerin (for acute angina pectoris);
  • Insulin, glucagon, and epinephrine auto-injectors (emergency or life-sustaining products that need pharmacist advice at release);
  • Oral dimenhydrinate (misuse potential; NAPRA advises against self-selection display where abuse is a concern) and permethrin for scabies.

Schedule III: "Pharmacy-Only" / Professional Services Area

• Dispensing Requirement: Sold over-the-counter without a prescription and without mandatory pharmacist intervention, but only from a licensed pharmacy.
• Storage and Access: Located in the Professional Services Area of the pharmacy, an area next to the dispensary where the pharmacist is available, accessible and approachable to answer patient questions and offer consultation. NAPRA describes the area by pharmacist availability, not by a fixed distance.
• Rationale: The self-selection of these products carries moderate risks (e.g., masking symptoms of a serious disease, significant drug-drug interactions, or specific organ toxicities) that benefit from the immediate availability of professional advice, even if an intervention is not mandatory for every purchase.
• Key Clinical Examples:
  • Oral diphenhydramine (sedating antihistamine with anticholinergic risk in older adults);
  • Levonorgestrel 1.5 mg emergency contraception;
  • Famotidine 20 mg or less per unit in packages containing more than 600 mg (smaller packages are unscheduled);
  • Fluconazole 150 mg single oral dose for vaginal candidiasis, and polymyxin B ophthalmic antibacterial drops.

Prescription ophthalmic antihistamines such as ketotifen, olopatadine and levocabastine are on the Prescription Drug List (Schedule I), not Schedule III.

Unscheduled: General Retail Outlets

• Dispensing Requirement: May be sold from any retail outlet (supermarkets, convenience stores, gas stations, vending machines) without any pharmacy licensing or healthcare professional presence.
• Rationale: The drug has a wide safety margin, treats an easily self-diagnosable condition, has negligible potential for abuse or dangerous interactions, and contains clear, plain-language packaging directions that enable safe consumer use without professional oversight.
• Key Clinical Examples:
  • Low-count packages of plain acetaminophen (325 mg or 500 mg tablets);
  • Low-count packages of ibuprofen 200 mg;
  • Antacid chewable tablets (calcium carbonate, aluminum/magnesium hydroxide);
  • Topical hydrocortisone 1% or less (exempt from the Prescription Drug List and not listed in the National Drug Schedules);
  • Throat lozenges, saline nasal rinses, and barrier topical emollients.

---

NAPRA Model Standards of Practice for Canadian Pharmacists

The NAPRA Model Standards of Practice for Canadian Pharmacists define the national benchmark for professional competence, accountability, and clinical practice quality. Adopted or adapted by each provincial regulatory authority, these standards establish enforceable expectations across core professional domains:

1. Patient-Centered Care and Clinical Assessment:
   • Pharmacists must conduct comprehensive patient assessments before initiating, adapting, renewing, or dispensing any drug therapy.
   • Identify, prioritize, resolve, and prevent Drug Therapy Problems (DTPs), evaluating appropriateness of indication, dosage regimen, efficacy, and safety.
2. Collaboration and Patient Advocacy:
   • Engage in structured interprofessional collaboration with prescribers, allied health providers, and caregivers, communicating clinical recommendations with clear documentation.
3. Dispensing Verification and Product Release:
   • Perform an independent clinical check and technical check on all prescription orders.
   • Ensure appropriate packaging, child-resistant closures, and clear, unambiguous auxiliary warning labels.
4. Communication and Patient Education:
   • Deliver tailored, interactive patient counseling that confirms understanding of therapeutic goals, administration timing, common adverse effects, and self-monitoring strategies.
5. Quality Improvement and Safety Culture:
   • Actively participate in Continuous Quality Improvement (CQI) programs, reporting medication incidents and near misses to anonymous national safety databases (such as ISMP Canada's Community Pharmacy Incident Reporting [CPhIR] system) to foster systemic safety improvements.